HOME >> BIOLOGY >> NEWS
Millennium's LDP(PS)-341 inhibits growth and induces death of cancer cells, appears to overcome chemotherapy resistance

LDP-341 Press release and fact sheet on multiple myeloma:

-Clinical and preclinical data presented at American Society for Hematology Meeting-

-Additional clinical trials planned with National Cancer Institute -

San Francisco, Dec. 4, 2000 -- Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced the presentation of preclinical and clinical study results demonstrating that an investigational proteasome inhibitor, LDP-341 (formerly PS-341), the first in a new class of anti-cancer agents, is active against multiple myeloma. The latest findings were presented at the 42nd Annual Meeting of the American Society of Hematology (ASH) meeting in San Francisco.

The first presentation, entitled "The Proteasome Inhibitor PS-341 Inhibits Growth, Induces Apoptosis and Overcomes Drug Resistance in Human Multiple Myeloma (MM) Cells," was based on research conducted by Teru Hideshima, M.D., Ph.D., and colleagues at Dana-Farber Cancer Institute and Harvard Medical School in collaboration with Millennium. In the preclinical study, LDP-341, a proprietary small molecule compound, showed in vitro activity against multiple myeloma cells, resulting in the inhibition of cancer cell growth and reproduction, and the inducement of cell suicide (apoptosis), in animals. The potent anti-tumor action of LDP-341 on multiple myeloma cells in these preclinical studies appears to involve both direct (apoptosis) and indirect inhibition of growth factors that promote tumor growth. In addition, in animals LDP-341 appears to increase the effectiveness of other anti-cancer drugs by overcoming cellular resistance, which in humans is a major cause of chemotherapy failure.

Clinical research was presented at the meeting by Thomas Stinchcombe, M.D., and principal investigator Robert Orlowski, M.D., Ph.D., in a report entitled "PS-341 is Active in Multiple Myeloma: Preliminary Report of a Phase I Trial of the Proteasome
'"/>

Contact: Lynn Smiledge, Millennium
617-761-4700
Porter Novelli
4-Dec-2000


Page: 1 2 3 4 5 6

Related biology news :

1. Marijuana ingredient inhibits VEGF pathway required for brain tumor blood vessels
2. The amendment to the law on green Genetic Engineering inhibits innovation and research in Germany
3. Inhibition of cathepsin proteases inhibits tumor formation in transgenic mice
4. Obesity drug inhibits prostate tumor growth
5. Protein inhibits cell growth, may contribute to breast cancer
6. ENBREL combo therapy inhibits joint damage progression, offers significant RA symptom relief
7. Aspirin inhibits ovarian cancer growth, lab study finds
8. UIC chemists identify compound that inhibits cell migration
9. UT Southwestern researchers find protein that both instigates, inhibits heart growth in mice
10. Bile acid inhibits cell death in Huntingtons disease
11. Researchers explain how protein inhibits angiogenesis

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/13/2017)... According to a new market research report "Consumer ... Administration, and Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - ... to grow from USD 14.30 Billion in 2017 to USD 31.75 Billion ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... NXT-ID, Inc. (NASDAQ:   NXTD ) ("NXT-ID" or ... independent Directors Mr. Robin D. Richards and Mr. ... the company,s corporate governance and expertise. ... Gino Pereira , Chief Executive Officer said," ... and benefiting from their considerable expertise as we move forward ...
(Date:4/5/2017)... LONDON , April 4, 2017 KEY ... is anticipated to expand at a CAGR of 25.76% ... neurodegenerative diseases is the primary factor for the growth ... full report: https://www.reportbuyer.com/product/4807905/ MARKET INSIGHTS The ... of product, technology, application, and geography. The stem cell ...
Breaking Biology News(10 mins):
(Date:10/10/2017)... 2017 International research firm Parks Associates announced today ... the TMA 2017 Annual Meeting , October 11 in ... home security market and how smart safety and security products impact the ... Parks Associates: Smart Home Devices: ... "The residential security market has experienced ...
(Date:10/9/2017)... , Oct. 9, 2017  BioTech Holdings ... mechanism by which its ProCell stem cell therapy ... limb ischemia.  The Company, demonstrated that treatment with ... of limbs saved as compared to standard bone ... molecule HGF resulted in reduction of therapeutic effect.  ...
(Date:10/9/2017)... (PRWEB) , ... October 09, ... ... published on October 5, 2017, in the medical journal, Epilepsia, Brain Sentinel’s ... the gold standard, video EEG, in detecting generalized tonic-clonic seizures (GTCS) using ...
(Date:10/6/2017)... Boston, Mass. (PRWEB) , ... October 06, 2017 ... ... spotlight female entrepreneurship within the healthcare and technology sector at their fourth annual ... six panels featuring 30 inspiring speakers and the ELEVATE pitch competition showcasing early ...
Breaking Biology Technology:
Cached News: